München und Göttingen, 8. Februar 2005 – Mit aktiver Unterstützung Ascenions wurde kürzlich das erste neue Unternehmen aus dem Deutschen Primatenzentrum (DPZ) heraus gegründet, die Encepharm GmbH.
Encepharm führt im Kundenauftrag Forschungsprojekte und vor-klinische Studien auf dem Gebiet psychischer und neuro-degenerativer Erkrankungen durch.…
München, 15. September 2004 – Das Deutsche Primatenzentrum (DPZ), das Forschungsinstitut für Molekulare Pharmakologie (FMP) und das Institut für Pflanzengenetik und Kulturpflanzenforschung (IPK) haben jeweils eine Partnerschaft mit der Ascenion GmbH geschlossen, um die kommerzielle Verwertung ihrer Forschungsergebnisse weiter voranzutreiben. Das…
Serotonin (5-hydroxytryptamine, 5-HT) is a signaling molecule, which is often associated with its function in the CNS. However, more than 90% of the human body's 5-HT is produced in the gut, mainly in enterochromaffin cells, and acts as peripheral 5-HT. 5-HT which is secreted in the gut is taken up by platelets acting as storage and is thus…
Oral Antimotilin-Based Inhibitors for Treating Helicobacter pylori Infections (TO 02-00372)
02-00372
Active2 compound reduces colonization in a H. pylori mouse model, shown with CFU (left) and gene expression (right) from stomach corpus samples (modified from Suerbaum et. al., 2022).
Novel small molecules that specifically inhibit the…
The ASGPR-CAR – a liver-specific chimeric antigen receptor (TO 15-00750)
15-00750
“Homing” of murine Treg cells expressing an ASGPR-CAR into liver tissue.
The novel technology reveals a liver-specific chimeric antigen receptor (CAR) targeting the Asialoglycoprotein-Receptor (ASGPR). Noteworthy, ASGPR is predominantly expressed on hepatocytes…
Novel CARs for the Treatment of Multiple Sclerosis and Alzheimer´s Disease (TO 15-00785)
15-00785
Treg cells expressing a MBP-specific CAR are mainly detectable in brain and spinal cord.
The invention introduces novel Chimeric Antigen Receptors (CARs) that are expressed in regulatory T-cells (Tregs) and enable targeted immunosuppression…
FAP-targeted dual imaging for guided cancer surgery (TO 42-00086)
42-00086
The invention presents a new class of zwitterionic, cyanine-based near-infrared (NIR) fluorophores, chemically linked to a scaffold that incorporates two ligands targeting the fibroblast activation protein (FAP). These compounds are distinct due to their sterically…
Spider silk/fibrin implant for the regeneration of injured spinal cord (TO 15-00617)
15-00617
Schematic depiction of the implant. Dense fibrin tube containing longitudinally orientated spider silk held in position by a fibrin filling (Koop et al. 2022)
The invention introduces a novel neural implant composed of a fibrin sheath containing…
Injection tunnel for stress-reduced handling of laboratory mice (TO 32-00174)
32-00174
Fig 1. Prototype of the injection tunnel
The present invention describes a specially developed injection tunnel that greatly simplifies the administration of injections (both intraperitoneally as well as intravenously) as well as tail vein blood sampling…
Method for Assessing Out-of-Specification (OOS) CAR T-Cell Products and Predicting Patient Response (TO 32-00128)
32-00128
Fig 1. The absolute number of therapeutically effective CAR-T cells determines therapy response
This innovation presents a novel diagnostic approach for predicting the therapeutic response of patients subjected to…
Method for direct measurement of functional avidity of T cells (TO 32-00222)
32-00222
Fig. 1: Rapid determination of T cell avidity (modified after L. Loyal)
This innovation presents a groundbreaking, rapid, scalable and automatable method for directly measuring the avidity of T cells, which is crucial for immune response…
Cytotoxicity Assay for detecting Cellular Damage (TO 10-00126)
10-00126
Luciferase reporter system based on Nluc cells
The technology provides a quick, easy, robust, highly sensitive, and inexpensive in vitro assay for measuring cell damage by using a new luciferase reporter system based on a genetically modified eukaryotic cell that stably…
Functionalized Nanoparticles for Viral Clearance (TO 10-00128)
10-00128
Mode of action of functionalized nanoparticles
This invention introduces a novel approach for the prevention and treatment of viral infections using functionalized nano- or microparticles. These particles are equipped with virus-binding peptides or small molecules…
Thiourea-Based Antibiotics against Acinetobacter baumannii (TO 02-00415)
02-00415
Original molecule structure (Shuka et al. 2018)
Small molecule thiourea-based antibacterial with remarkable activity against Acinetobacter baumannii and other Acinetobacter species, including MDR strains.
Novel antibiotic candidate to curb AMR in Gram-negative…
Inhibitors of Energy Coupling Factor (ECF) Transporters Against Gram-Positive Pathogens (TO 02-00404)
02-00404
Survival of G. mellonela larvae after infection with S. pneumoniae (modified from Shams et. al., 2024).
Novel class of antimicrobial agents that specifically target Energy-Coupling Factor (ECF) transporters in Gram-positive…
Gene editing of the proteinase 3 autoantigen as a novel treatment for ANCA-associated vasculitis (TO 32-00200)
32-00200
Effects of PR3 gene editing in HSPC-derived neutrophils. Source: Jerke et al., Kidney Int. 2025
The technology provides a novel approach for treating proteinase 3 (PR3)-specific anti-neutrophil cytoplasm antibody…
